Cutaneous Squamous Cell Carcinoma Treatment Market, by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy)), by

Cutaneous Squamous Cell Carcinoma Treatment Market, by Treatment (Surgical (Moh’s Micrographic Surgery (MMS) and Electrodessication or Curettage), Non-surgical (Chemotherapy, Topical Immune Response Modifiers, Radiotherapy, and Systemic Chemotherapy)), by Application (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study:
This report provides in-depth analysis of the global cutaneous squamous-cell carcinoma treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cutaneous squamous-cell carcinoma treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global cutaneous squamous-cell carcinoma treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cutaneous squamous-cell carcinoma treatment market.
Detailed Segmentation:
Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
Global Cutaneous Squamous Cell Carcinoma Treatment Market, By Region:
North America
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country:
U.S.
Canada
Latin America
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Treatment:
Surgical
Moh’s Micrographic Surgery (MMS)
Electrodessication or Curettage
Non-surgical
Chemotherapy
Topical Immune Response Modifiers
Radiotherapy
Systemic Chemotherapy
By Application:
Hospitals
Cancer Institutes
Ambulatory Surgical Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Eli Lilly and Company*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Sanofi S.A.
Cadila Healthcare Limited.
Cipla Limited
Castle Biosciences
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
Vidac Pharma
LEO Pharma A/S
Regeneron Pharmaceuticals, Inc.
Merck Sharp & Dohme
Amgen Inc.
“*” marked represents similar segmentation in other categories in the respective section.